In a pivotal stride to address the growing AFib epidemic, OMRON Healthcare today announced the U.S. Food and Drug ...

OMRON Healthcare has received de novo authorization from the U.S. Food and Drug Administration (FDA) to market new home blood pressure monitors featuring AI-powered atrial fibrillation ...

Exposure to extreme heat may double or triple the risk of irregular heart rhythms in people with implanted defibrillators, ...

PRNewswire New York [US] 13 Fourth Frontier a medical technology company based out of New York and Bangalore announced the ...

A hospital in Pittsburgh has become the latest medical center to join a ground-breaking Apple Watch trial in the US that's ...

Adding an extra hour every week of physical activity may lower the chance of developing the most common type of irregular heartbeat (arrythmia) by 11 percent, a new study shows.

The FDA has granted a de novo clearance to a wearable device—with a form factor you’re familiar with—that can check patients ...

Fourth Frontier has achieved a crucial milestone with the FDA's clearance of the Frontier X Plus, a single-lead ECG monitor. Positioned to enhance heart health monitoring, this wearable device ...

If left untreated, this can lead to stroke, heart failure, and other issues ... Heffron notes that in the sole earlier study ...

The trial uses an Apple smartwatch to monitor episodes of AFib, a heart rhythm disorder that can lead to blood clots and strokes. If patients are able to go 30 days without an episode, they can ...

The Frontier X Plus is an innovative single-lead, continuous ECG monitor that is ... The American Heart Association reports ...